To gain insights into the potential systemic antitumor efficacy of ISIM treatment of mice bearing orthotopic mammary tumors with brain metastasis, we evaluated the phenotype of CD4+ and CD8+ T cells in the spleens of untreated or ISIM-treated mice by flow cytometry (Fig. 2a). The gene discussed is CD8A; the disease is breast cancer.